N*2*,N*2*-Diethyl-2-methyl-N*1*-(6-phenyl-5-propyl-pyridazin-3-yl)-propane-1,2-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N*2*,N*2*-Diethyl-2-methyl-N*1*-(6-phenyl-5-propyl-pyridazin-3-yl)-propane-1,2-diamine
• 英文别名: 2-N,2-N-diethyl-2-methyl-1-N-(6-phenyl-5-propylpyridazin-3-yl)propane-1,2-diamine
• 化学式: C₂₁H₃₂N₄
• 分子量: 340.5
• InChiKey: UPNNBTDQWUFTGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Dérivés de la pyridazine, procédé de préparation et compositions pharmaceutiques en contenant
  申请人：SANOFI

  公开号：EP0429344B1

  公开（公告）日：1996-09-18
• FORMULATION PHARMACEUTIQUE LYOPHILISEE STABLE
  申请人：SANOFI-SYNTHELABO

  公开号：EP0858325B1

  公开（公告）日：2002-07-31
• Cholineterase inhibitors for treating inflammation
  申请人：Tracey J. Kevin

  公开号：US20080070901A1

  公开（公告）日：2008-03-20

  A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.
• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20110319386A1

  公开（公告）日：2011-12-29

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
• METHODS OF TREATMENT OF FATTY LIVER DISEASE BY PHARMACOLOGICAL ACTIVATION OF CHOLINERGIC PATHWAYS
  申请人：Pavlov Valentin A.

  公开号：US20120322719A1

  公开（公告）日：2012-12-20

  A method of treating a fatty liver disease in a subject. The method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis, and alcoholic cirrhosis.